<DOC>
	<DOCNO>NCT01031901</DOCNO>
	<brief_summary>This study prospective , randomize , double-blind , placebo-controlled evaluation safety topically apply formulation rapamycin cutaneous fibromatous lesion subject Tuberous Sclerosis Complex ( TSC ) Neurofibromatosis I ( NF1 ) . Subjects apply either Polyvinylidene fluoride ( PVDF ) coating ( Skincerity ) contain rapamycin PVDF coat alone nightly fibromatous lesion duration six month . The primary goal study evaluate safety topical product patient TSC NF1 . The secondary goal study evaluate effectiveness topical product treatment cutaneous fibromatous lesion .</brief_summary>
	<brief_title>Topical Rapamycin Therapy Alleviate Cutaneous Manifestations Tuberous Sclerosis Complex ( TSC ) Neurofibromatosis I ( NF1 )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Angiofibroma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<criteria>Subject willing able comply trial requirement Subject male female 13 year age Subject diagnosis either TSC NF1 visible fibromatous lesion ( angiofibromas neurofibroma ) Female subject childbearing potential must pregnant must agree use appropriate contraceptive method duration trial Subject currently receive therapy rapamycin sirolimus Subject receive form immunosuppression previously experience immune dysfunction Subject currently participate participate within last 30 day clinical trial involve investigational drug Subject know hypersensitivity either PVDF coating ( SkincerityÂ® ) rapamycin Subject pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Tuberous Sclerosis</keyword>
	<keyword>Neurofibromatoses</keyword>
	<keyword>Angiofibroma</keyword>
	<keyword>Neurofibroma</keyword>
	<keyword>Sirolimus</keyword>
</DOC>